## INFECT Strong together against infections CONTROL Science • Society • Industry

# Vaccine development with an emphasis on the cooperation of industry and science

VacoME - Development of vaccines against respiratory and systemic infections in humans and pigs

Dr. Peter Schmid Director Pharma Innovation Ceva Santé Animale, France

GEFÖRDERT VOM





wanzig**2**0


Bundesministerium für Bildung und Forschung



## VacoME –

Development of vaccines against respiratory and systemic infections in humans and pigs


- Vaccine research and development
- VacoME as an example of an interdisciplinary One Health approach
  - Objectives
  - Disciplines and working groups involved
  - Results
  - Achievements due to the interdisciplinary One Health approach
- Outlook







#### Vaccine research and development





Objectives

In a trans-sectoral approach, antigens should be identified which provide broad cross serotype protection against *S. suis* 

- Identification of host compartment-specific antigens in S. suis (nasopharynx, lung, blood, CSF)
  - *In vivo* and *ex vivo* proteomics
  - RNAseq analyses
- Recombinant production and purification of potentially immunogenic AG candidates
- Immunoproteome analyses by convalescent sera from pigs
- Immunization with multi-component vaccine prototypes and testing of the protective effect in challenge experiments in pigs
- Identification of *ex vivo* correlates for protective immunity



#### Disciplines and working groups involved







#### UNIVERSITÄT LEIPZIG

Vet.med. Fakultät VM

Bacteriology and Mycology



UNIVERSITÄT LEIPZIG

Vet.med. Fakultät VMF

Immunology







Results

The objective of cross serotype protection against *S. suis* was not achieved, but,

- the immunoproteomics application was established and validated;
- a spectral database for *S. suis* was created;
- a large number of *S. suis* proteins have been identified which are differentially expressed *in vivo* (>100) in a compartment-specific manner;
- 52 antigen candidates were identified by immunoproteomics (significant difference between sera from convalescent and susceptible pigs);
- a multicomponent vaccine was produced from 6 antigens;
- this vaccine resulted in high antibody titres but no protection in the challenge test;
- the *S. suis*-induced oxidative burst in blood granulocytes was established as a new *in vitro* correlate of protection.




Achievements due to the interdisciplinary One Health approach

- Immunoproteomics based identification of putative cross-protective antigens
- S. suis-induced oxidative burst in blood granulocytes as an *in vitro* correlate of protection




## Immunoproteomics-based approach to identify putative cross-protective antigens



**INFE ≪T** 

#### New *in vitro* correlate of protection: *S. suis*-induced oxidative burst in blood granulocytes







#### Outlook

PathoWIKI 2020-2021: Development of pathogen-specific databases (WIKI) for *S. suis* and *S. pneumoniae* as a basis for the analysis and application of OMICS data for vaccine development



## Acknowledgements

UNIVERSITÄT GREIFSWALD Wissen lockt. Seit 1456



Sven Hammerschmidt Mohammed Abdullah Franziska Voß & international/national partner

Universitätsmedizin Uwe Völker Denise Dittmar

Petra Hildebrandt Stephan Michalik

Ulrike Mäder

#### UNIVERSITÄT LEIPZIG

Vet.med. Fakultät VMI

Bacteriology and Mycology

Christoph Baums Christine Weiße Viktoria Rungelrath

#### UNIVERSITÄT LEIPZIG

Vet.med. Fakultät VM

Immunologie Gottfried Alber Nicole Schütze



Susanne Häußler Astrid Dröge Ariane Khaledi



Volker Florian Beata Jakóbczak



Dominik Driesch Daniela Albrecht-Eckardt Sebastian G. Henkel

GEFÖRDERT VOM







Bundesministerium für Bildung und Forschung

INFE CT CONTROL